Healthcare · Biotechnology
Price
$0.11
Market Cap
$2.8M
Employees
3
Beta
0.70
Avg Volume
10,257,443
CEO
Chris Kim
Business Description
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Business History
Price Overview
Last updated: Jun 27, 2026 10:05am (just now)$0.11
+0.01 (+6.77%)
Day Range
$0.10 – $0.11
52-Week Range
$0.10 – $12.90
50-Day MA
$0.17
200-Day MA
$0.69
Volume
810,994.00
Share Structure
Outstanding
26,833,407.00
Float
8,073,741.00
Free Float
30.1%
Moderate free float
— 30.1% of shares trade freely, ~69.9% held by insiders/institutions
Reasonable but insiders still hold a significant stake. This can be positive (skin in the game) but may limit liquidity during sell-offs.
Small absolute float (8.1M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.25
Stock Price: $0.11
EPS (Diluted): -0.43
EPS (Diluted): -0.43
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-1.48
Stock Price: $0.11
Total Equity: -$9.81M
Shares: 23,753,561
Total Equity: -$9.81M
Shares: 23,753,561
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.22
Market Cap: $2.84M
Total Debt: $1.44M
Cash: $337,655
EBITDA: -$9.99M
Total Debt: $1.44M
Cash: $337,655
EBITDA: -$9.99M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$15.6M
Market Cap: $2.84M
Total Debt: $1.44M
Cash: $337,655
Total Debt: $1.44M
Cash: $337,655
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $0.11
Revenue: $0.00
Shares: 23,753,561
Revenue: $0.00
Shares: 23,753,561
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$2.97M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$10.21M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
215.7%
Net Income: -$10.21M
Total Equity: -$9.81M
Total Equity: -$9.81M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-283.2%
Operating Income: -$2.97M
Tax Rate: 0.0%
Equity: -$9.81M
Total Debt: $1.44M
Cash: $337,655
Tax Rate: 0.0%
Equity: -$9.81M
Total Debt: $1.44M
Cash: $337,655
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.05
Current Assets: $500,574
Current Liabilities: $10.30M
Current Liabilities: $10.30M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
-0.15
Short-Term Debt: $1.44M
Long-Term Debt: $0.00
Total Debt: $1.44M
Total Equity: -$9.81M
Long-Term Debt: $0.00
Total Debt: $1.44M
Total Equity: -$9.81M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 23,753,561
Shares: 23,753,561
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-0.41
Total Equity: -$9.81M
Shares: 23,753,561
Shares: 23,753,561
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.42
Operating CF: -$9.96M
CapEx: -$13,108
Shares: 23,753,561
CapEx: -$13,108
Shares: 23,753,561
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.11
Stock Price: $0.11
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$10.21M
Net Income: -$10.21M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares LIMN against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 22, 2026 6:41pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Expenses | $2.5M | $2.7M | $2.6M | $2.9M | $3.0M |
| Operating Income | -$2.5M | -$2.7M | -$2.6M | -$2.9M | -$3.0M |
| Net Income | $4.4M | -$2.9M | -$1.2M | -$2.9M | -$10.2M |
| EBITDA | $4.4M | -$2.7M | -$1.1M | -$2.7M | -$10.0M |
| EPS | $0.13 | $-0.08 | $-0.15 | $-0.40 | $-0.43 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 22, 2026 6:41pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $336,228 | $5.0M | $434,000 | $804,538 | $337,655 |
| Total Current Assets | $421,922 | $360,649 | $210,881 | $812,658 | $500,574 |
| Total Assets | $276.4M | $15.5M | $4.5M | $2.8M | $512,795 |
| Current Liabilities | $1.4M | $3.6M | $5.2M | $8.7M | $10.3M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $21.6M | $14.2M | $15.2M | $18.7M | $10.3M |
| Total Equity | $254.9M | $1.3M | -$10.7M | -$15.9M | -$9.8M |
| Retained Earnings | -$21.1M | -$14.0M | -$14.9M | -$17.5M | -$38.9M |
Cash Flow (Annual)
Last updated: Jun 22, 2026 6:41pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M | $-869,000 | -$3.3M | -$3.1M | -$10.0M |
| Capital Expenditure | $0 | $0 | $0 | $0 | $-13,108 |
| Free Cash Flow | -$1.2M | $-869,000 | -$3.3M | -$3.1M | -$10.0M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $4.4M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $-700,000 | -$10.7M | -$1.8M | $0 |
| Net Change in Cash | $336,228 | $5.0M | -$4.6M | $648,113 | $281,336 |
Growth Trends (YoY %)
Last updated: Jun 22, 2026 6:41pm (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -6.9% | +4.5% | -12.4% | -2.1% |
| Net Income Growth | -167.0% | +58.1% | -136.9% | -251.4% |
| EBITDA Growth | -162.0% | +59.8% | -152.2% | -263.6% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2025-04-30 | Iris Acquisition Holdings LLC | 0.00 | $0.00 | $0 | |
| 2025-07-10 | Lemons II Philip Wayne | 0.00 | $0.00 | $0 | |
| 2025-07-10 | Baek Richard JaiHwan | 0.00 | $0.00 | $0 | |
| 2025-04-30 | KH Feelux Co., Ltd | 0.00 | $0.00 | $0 | |
| 2025-04-30 | Valetudo Therapeutics LLC | 0.00 | $0.00 | $0 | |
| 2025-04-30 | Lee Eun Sook | 0.00 | $0.00 | $0 | |
| 2025-04-30 | Baek Ji Yeon | 0.00 | $0.00 | $0 | |
| 2025-04-30 | Kim Chris | 0.00 | $0.00 | $0 | |
| 2025-04-30 | Choi Beom Kyu | 0.00 | $0.00 | $0 | |
| 2025-04-30 | Yoo Byong Chul | 0.00 | $0.00 | $0 | |
| 2025-04-30 | Lee Sang-Jin | 0.00 | $0.00 | $0 | |
| 2025-04-30 | Fernandez Nicholas | 0.00 | $0.00 | $0 | |
| 2025-04-30 | Dam Scott | 0.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for LIMN — it's generated by the pipeline (
market-narrative step).
No community reviews yet for LIMN.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30